Barzolvolimab Retreatment Shows Profound Efficacy in Cold Urticaria and SD, Reinforcing Best-in-Class Profile
CLDX sits 99% above its 52-week low of $14.4.
Summary
Celldex Therapeutics presented new positive Phase 2 data for its lead asset, barzolvolimab, at the AAAAI 2026 meeting, demonstrating that retreatment in patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) achieved similar profound efficacy to initial exposure. Specifically, 62% of ColdU patients and 60% of SD patients achieved a complete response at Week 20 in the Open Label Extension, consistent with initial treatment rates. This data is significant as it reinforces barzolvolimab's potential as a 'first-in-class and best-in-disease' treatment by showing durable efficacy upon retreatment, which is critical for chronic conditions. This positive update further de-risks the ongoing global Phase 3 trial for barzolvolimab in ColdU and SD, which initiated in late 2025, and enhances the drug's long-term commercial outlook. Investors will now closely monitor the progress and eventual readout of this pivotal Phase 3 study.
At the time of this announcement, CLDX was trading at $28.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $14.40 to $31.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.